Amlodipine/Valsartan [Design Issues]

posted by Bebac user – Egypt, 2023-09-09 08:34 (670 d 11:49 ago) – Posting: # 23713
Views: 4,880

The combination of Amlodipine and valsartan was published as two periods crossover but after checking the variability of Valsartan, it had more than 30%. Therefore, should I in those cases design this study as replicated or un-replicated ?

Complete thread:

UA Flag
Activity
 Admin contact
23,430 posts in 4,931 threads, 1,679 registered users;
66 visitors (1 registered, 65 guests [including 7 identified bots]).
Forum time: 20:23 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5